This webinar proposes a short primer on stated preference methods and how they can be used to explore the patient preferences for specific drug profiles that are currently available or may be developed in the near future. The theory will be then discussed as applied to two case studies using quantitative preference methods.

In this one day course you will learn about the practicalities of running a phase I dose-finding Continual Reassessment Method (CRM) trial. During the day we will introduce the CRM design, run a CRM trial, provide training on the features in designing a CRM, move onto ideas in making a grant application, then planning in set-up and running of a CRM trial.

As the availability of big data increases and statisticians assist with predicting outcomes or understanding patterns in an ever-wider variety of scenarios then supervised and unsupervised learning methods become increasing called upon. Such machine learning algorithms offer the opportunity to understand potential predictors or clusters amongst large datasets, but are also subject to the risks of overfitting or over-interpretation. This Webinar seeks to introduce ideas and share experiences in this field.

Our next journal club, held jointly with the DIA, features two papers on the topic of Statistical Considerations for Innovative Designs in Clinical Trials. Please join us to hear Jason Yuan and Xiangmin Zhang present their recent work.

This meeting aims to bring together statisticians from the pharmaceutical industry and academia to hear about recent advances in statistical methods for quantitative decision-making in drug development.

The paper to be presented appeared earlier this year in Pharmaceutical Statistics (Weber, Hemmings, Koch, 17, 329-341) and is motivated by the opportunities and challenges for using Bayesian methods with informative priors to support drug development and licencing when only a small pool of patients is available, as in the case of rare diseases and paediatric population.

There is a simple equation for access in the UK: Access = Reimbursement + Uptake. Yet, whilst a simple and logical approach, each component is challenging to achieve. This webinar focuses on the National Reimbursement side: the National Institute for Health and Care Excellence (NICE) - who they are, what is involved in the Health Technology Appraisal (HTA) assessment, how they make decisions.

The draft ICH E9 addendum on estimands and sensitivity analysis was released back in July 2017 and (more than 1000) comments are back. All stakeholders are gaining the necessary experience and familiarity with estimands along with the associated challenges and methodologies. The language and thinking behind causal inference is well suited to this area.

Our annual PSI Medical Statistics Careers Event, will be held at the De Montfort University in Leicester on Wednesday 20th February 2019.

PSI are pleased to announce that the countdown to the 2019 Conference has begun! The theme for the conference is “Data Driven Decision Making in Medical Research”. The 2019 PSI Conference will take place at the Queen Elizabeth II Centre (QEII), London, from 2nd to 5th June 2019.

The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies from October 2019 to July 2020 to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 sessions in the UK. It promises to be a truly memorable course.